Jupiter – November 10, 2026 -- Myosin Therapeutics plans to move its MT-125 glioblastoma trial into Phase 2 in early 2027, with the Phase 1 dose-escalation stage running ahead of schedule, the company said ahead of the Society for Neuro-Oncology (SNO) meeting in Philadelphia.
CEO and CMO to meet investigators and prospective partners at SNO
CEO Courtney Miller and CMO Karen Smith will attend the 31st SNO Annual Meeting, running November 12-15, 2026. They will meet current clinical investigators and potential development partners to discuss the Phase 1/2 STAR-GBM trial and preparations for the Phase 2 transition.
Miller said the company's focus is on "solidifying the clinical and strategic relationships" needed for the next development stage.
STAR-GBM trial runs at three Mayo Clinic sites in Florida, Arizona and Minnesota
The NCI-supported study (NCT07185880) is evaluating MT-125 in patients with newly diagnosed, MGMT unmethylated glioblastoma (GBM). The Phase 2 expansion will test MT-125 in additional treatment regimens, including oral maintenance therapy and a synergistic combination treatment.
MT-125 holds FDA Orphan Drug and Fast Track designations
MT-125 is a first-in-class non-muscle myosin inhibitor. It targets the physical machinery cancer cells need to grow, divide, invade, metastasize, repair themselves and survive, rather than molecular signaling pathways. The FDA has granted it Orphan Drug Designation for malignant gliomas and Fast Track Designation for GBM. Two peer-reviewed publications in Cell support the underlying science.
Myosin plans clinical entry into two more cancers in 2027
Preclinical studies have shown MT-125's potential in solid and hematologic cancers, underpinning the company's plan to develop it as a pan-oncology therapeutic. Myosin intends to start clinical development in two additional cancer indications later in 2027, while continuing preclinical and translational work on other company assets.